In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNFA" or the "Company"), a clinical stage biopharmaceutical company committed to ...

Eli Lilly & Co. (NYSE: LLY) is a major global pharmaceutical company in the medical sector. The company made headlines with ...

Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...

With the holidays past and the new year arrived, we look ahead — to losing weight. For some that resolve theoretically ...

Type 2 diabetes is common; it affects one in ten adults internationally and one in five adults aged 65 years or older. It is ...

In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression of chronic ...

Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones of the metabolic franchiseBiomea preparing icovamenib for late-stage ...

Upcoming Investor Conference Skye Bioscience will be a corporate presenter at the 43 rd annual J.P. Morgan Healthcare Conference Thursday, January 16, 2025, at 10:30 AM - 11:10 AM and is available for ...

New Anglo/U.S. obesity and cardiometabolic specialist Verdiva Bio Ltd. has launched with a massive $411 million series A and ...

In a notable move, Hims & Hers Health donated $1 million to President-elect Donald Trump’s inauguration fund, signaling its ...

A collaboration between a drug plan and clinical pharmacists led to nearly 50% of members successfully switching to a preferred dipeptidyl-peptidase-4 inhibitor.